REGENXBIO Announces Presentations at the American Society of Gene & Cell Therapy 2019 Annual Meeting

ROCKVILLE, Md., April 15, 2019 /PRNewswire/ -- REGENXBIO Inc. RGNX, a leading clinical-stage biotechnology company seeking to improve lives through the curative potential of gene therapy based on its proprietary NAV® Technology Platform, today announced the presentation of four posters at the American Society of Gene & Cell Therapy (ASGCT) 2019 Annual Meeting in Washington, D.C., from April 29 to May 2, 2019.

The data will be presented as follows:

Abstract Title: Determination of AAV Genome Content and Capsid Content by Size Exclusion Chromatography (abstract #184)

Presenter: Brian Howie, Associate Scientist, REGENXBIO

Session Title: AAV Vectors

Date/Time: Monday, April 29, 2019, 5:00 p.m. to 6:00 p.m. ET

Location: Columbia Hall

Abstract Title: Assessing Purity and Structures of AAV Vector Genomes by High Performance Size Exclusion Chromatography (abstract #174)

Presenter: Li Zhi, Ph.D., Senior Scientist, REGENXBIO

Session Title: AAV Vectors

Date/Time: Monday, April 29, 2019, 5:00 p.m. to 6:00 p.m. ET

Location: Columbia Hall

Abstract Title: Structure-Guided Engineering of Surface-Exposed Loops on the AAV Capsid (abstract #466)

Presenter: Samantha Yost, Ph.D., Scientist I, REGENXBIO

Session Title: AAV Vectors II

Date/Time: Tuesday, April 30, 2019, 5:00 p.m. to 6:00 p.m. ET

Location: Columbia Hall

Abstract Title: Validation of AAV Transgene-Specific Quantification Assay Using BioRad Droplet Digital PCR (abstract #734)

Presenter: Scott Jenkins, Associate Scientist II, REGENXBIO

Session Title: AAV Vectors III

Date/Time: Wednesday, May 1, 2019, 5:00 p.m. to 6:00 p.m. ET

Location: Columbia Hall

About REGENXBIO Inc.

REGENXBIO is a leading clinical-stage biotechnology company seeking to improve lives through the curative potential of gene therapy. REGENXBIO's NAV Technology Platform, a proprietary adeno-associated virus (AAV) gene delivery platform, consists of exclusive rights to more than 100 novel AAV vectors, including AAV7, AAV8, AAV9 and AAVrh10. REGENXBIO and its third-party NAV Technology Platform Licensees are applying the NAV Technology Platform in the development of a broad pipeline of candidates in multiple therapeutic areas.

Contacts:

Investors:

Heather Savelle, 212-600-1902

heather@argotpartners.com

Media:

David Rosen, 212-600-1902

david.rosen@argotpartners.com

(PRNewsfoto/REGENXBIO Inc.)

 

Cision View original content to download multimedia:http://www.prnewswire.com/news-releases/regenxbio-announces-presentations-at-the-american-society-of-gene--cell-therapy-2019-annual-meeting-300832184.html

SOURCE REGENXBIO Inc.

Market News and Data brought to you by Benzinga APIs
Comments
Loading...
Posted In: Press Releasestrade shows
Benzinga simplifies the market for smarter investing

Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.

Join Now: Free!